Evotec SE announced that its biologics segment expanded a strategic partnership with Sandoz to provide biosimilars to the pharma company. Under the agreement, Evotec Biologics will receive appropriate remuneration following early scientific validation. Further funding will be tied to achieving development milestones from 2025. The expanded partnership solidifies the company’s commitment to providing a long-term…
Boehringer Ingelheim opens new green energy power plant
Boehringer Ingelheim announced today that it inaugurated a biomass powerplant at its Ingelheim, Germany site. The pharmaceutical company — one of the largest in the world — opened the new plant to optimize its energy supply and protect the environment. With the new plant, the company expects to save around 50,000 tons of CO2. It…
Sanofi, Novartis among Time’s most sustainable companies
Pharma giants Sanofi and Novartis came in at No. 7 and 17, respectively, in Time magazine’s “Most Sustainable Companies of 2024” rankings. Overall, nearly 40 of the 500 companies on the list fell under the category of Chemicals, Drugs & Biotechnology. Other large pharma companies making it into the top half of the 500 included…
Veranova to spend $30M on Massachusetts facility
Veranova recently announced that it will invest $30 million in its Devens, Massachusetts facility to expand its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities The Wayne, Pennsylvania–based company — a specialist in making active pharmaceutical ingredients — said the investment in the Devens plant will build upon the site’s existing development…
Novo Nordisk invests $4.1B to expand manufacturing operations in North Carolina
Novo Nordisk today announced plans to invest $4.1 billion to build a new manufacturing facility in North Carolina. The Denmark-based company will build a second fill and finishing manufacturing facility in Clayton, North Carolina, to grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Novo…
Emergent BioSolutions sells Baltimore manufacturing plant to Bora for $30M
Emergent BioSolutions this week announced it entered into a definitive agreement to sell its Baltimore-Camden drug product facility. The Gaithersburg, Maryland-based company will sell the facility to an affiliate of Bora Pharmaceuticals for approximately $30 million. Emergent’s Camden site is part of the company’s Contract Development and Manufacturing Organization (CDMO) and has clinical and commercial…
Thermo Fisher Scientific expands clinical research lab in Wisconsin
Thermo Fisher Scientific has expanded its clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. The new $58 million investment adds 72,500 sq ft. to the company’s footprint and increases the site’s chemistry, manufacturing, and control analytical capabilities for biopharmaceutical therapy development. “As research in biopharmaceutical therapies continues to rapidly…
Kyowa Kirin board approves new $530M biologics plant in North Carolina
Kyowa Kirin announced that its board of directors approved plans to invest up to $530 million to build a new pharmaceutical manufacturing facility. The Japan-based company plans to build a new, state-of-the-art facility in Sanford, North Carolina. It expects the 171,700-square-foot, two-reactor facility to accelerate the development and production of biologic therapies for rare and…
Vetter expands manufacturing capacity in the U.S. and Germany
Vetter recently announced it is expanding its development services sites in the U.S. and is planning for major investments in Germany. The company announced plans to move and expand its Development Services site from Skokie, Illinois, to Des Plaines, Illinois. It plans to invest majorly in its commercial business in Saarland, Germany, to complement its…
Molecular Devices opens U.K. facility to make patient-derived organoids
Molecular Devices recently announced it opened its custom-built bioanalytical site in the U.K. The new facility is based in Cardiff, Wales, and is custom-built for the company’s bioprocess workflow and unique bioreactor technology. Molecular Devices’ biotechnology allows pharmaceutical companies to manufacture patient-derived organoids (PDOs) at scale in a quality-controlled manner. “Molecular Devices is the only…